Also part of the UPMC family:

The McGowan Institute for Regenerative Medicine

Merging Science with Technology to Treat Disease

Regenerative medicine uses clinical procedures to repair or replace damaged or diseased tissues and organs, versus some traditional therapies that just treat symptoms.

To realize the vast potential of tissue engineering and other techniques aimed at repairing damaged or diseased tissues and organs, the University of Pittsburgh School of Medicine and UPMC established the McGowan Institute for Regenerative Medicine. The McGowan Institute serves as a single base of operations for the University’s leading scientists and clinical faculty working to develop tissue engineering, cellular therapies, and artificial and biohybrid organ devices.

The McGowan Institute is the most ambitious regenerative program in the nation, coupling biology, clinical science, and engineering. Success in our mission will impact patients’ lives, bring economic benefit, serve to train the next generation of researchers, and advance the expertise of our faculty in the basic sciences, engineering, and clinical sciences. Our efforts proudly build upon the pioneering achievements of the Thomas E. Starzl Transplantation Institute.

While there are certain select therapies based on regenerative medicine principles now in clinical use, much work lies ahead to realize the potential of this growing field. Advances in the underlying science, engineering strategies to harness this science, and successful commercial activities are all required to bring new therapies to patients.

Regenerative Medicine Podcasts

The McGowan Institute sponsors a podcast series on regenerative medicine. Listen to some of the world's leading regenerative medicine researchers and physicians talk about their work.

Listen to the most recent podcasts.

News and Events

Medical Devices Lab Technology May Help COVID-19 Patient

Under the direction of McGowan Institute for Regenerative Medicine faculty member William Federspiel, PhD, the William Kepler Whiteford Professor in the Department of Bioengineering at the University of Pittsburgh, the Institute’s Medical Devices Laboratory is developing clinically significant devices for the treatment of pulmonary and other cardiovascular ailments by utilizing the engineering principles of fluid flow and mass transfer.

UPMC-Led Global Effort Fast Tracks Testing of COVID-19 Therapies 

Launched recently at UPMC is a novel clinical trial developed by researchers at the University of Pittsburgh School of Medicine to address one of the most important debates during the COVID-19 pandemic: How should doctors decide between quickly adopting new therapies, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials?

COVID-19 Vaccine Candidate Shows Promise

University of Pittsburgh School of Medicine scientists announced a potential vaccine against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic. When tested in mice, the vaccine, delivered through a fingertip-sized patch, produces antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing the virus.

UPMC Close to Immunity Test that Could Help End COVID-19 Lockdown 

As reported by David Templeton for the Pittsburgh Post-Gazette, UPMC researchers are close to completing a blood test to determine immunity against the virus that causes COVID-19.  Such a test could certify little or no risk of SARS-CoV-2 infection and identify the so-called “super” people who could serve in the health-care battle against COIVD-19 with little risk to themselves.

More News and Events